You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. AFM based nanoscale IR Spectroscopy (AFM-IR) as a characterization platform for P

    SBC: Anasys Instruments Corp.            Topic: 300

    DESCRIPTION provided by applicant Anasys Instruments and Prof Lynne Taylor of Purdue propose to develop nanoscale chemical characterization capabilities for drug formulation research This project will build on successful Phase I research demonstrating feasibility of atomic force microscope based infrared spectroscopy AFM IR in pharmaceutical applications This Phase II research will advance ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A high-throughput kit for detection of RNA modifications

    SBC: MAVERIX BIOMICS, INC.            Topic: NIDA

    DESCRIPTION provided by applicant The broad objective of this project is to develop an integrated wet lab dry lab kit for high throughput detection of RNA modifications The final product will provide all required molecular biology reagents a set of simple and robust experimental manipulations for facile analysis of modifications and researcher friendly analytic cloud based software requi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. A hormonal therapy for preeclampsia

    SBC: ADEPTHERA, LLC            Topic: NICHD

    DESCRIPTION provided by applicant Preeclampsia is a pregnancy specific hypertensive disorder that can lead to multi organ failure seizure and maternal death Preeclampsia is also responsible for as many as of premature births in the United States Although better neonatal care has improved the likelihood of preterm babies surviving many face increased mortality and serious long term mor ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. A new generation of targeted therapeutics for the treatment of cancer

    SBC: NERX BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. A new treatment for NSAID-associated gastrointestinal damage

    SBC: Anteana Therapeutics Inc            Topic: NIDDK

    DESCRIPTION provided by applicant Non steroidal anti inflammatory drugs NSAIDs are among the most widely consumed pharmaceuticals but their prolonged use causes gastric injury and damage to the small intestine Previous work has shown that anandamide an endogenous endocannabinoid substance produced in the gastrointestinal GI mucosa plays an important role in epithelial homeostasis and re ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. A novel diagnostic test for Irinotecan and Topotecan sensitivity

    SBC: RG Biopharma            Topic: NCI

    DESCRIPTION (provided by applicant): The long term objective of this Phase 1 study is to produce an antibody-based diagnostic assay to detect tumor responsiveness to a widely used class of chemotherapeutic agents derived from camptothecin that includes Irinotecan and Topotecan. The assay will be based on a novel biomarker associated with cellular sensitivity to camptothecin and will have clinical ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. A novel vaccine against vaginal Chlamydia trachomatis

    SBC: EPITOGENESIS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. ASC101 Enhancement of Regenerative Capacity of Amniotic Fluid-derived Stem Cells

    SBC: TARGAZYME, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): In the present STTR we propose to investigate two novel approaches in our exploration of the therapeutic and regenerative potential of cell-based medicine. Furthermore, we will utilize a preclinical animal model of compression syndrome (CS) that mimics the pathophysiology of multiple injuries such as crush injuries, burns, circulation blockage, fractures, hemor ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government